دورية أكاديمية
أعرض في EDS

Systemic biomarker associated with poor outcome after futile reperfusion.

التفاصيل البيبلوغرافية
العنوان: Systemic biomarker associated with poor outcome after futile reperfusion.
المؤلفون: Hervella P; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Sampedro-Viana A; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Rodríguez-Yáñez M; Stroke Unit, Department of Neurology, Hospital Clínico Universitario, A Coruña, Spain., López-Dequidt I; Stroke Unit, Department of Neurology, Hospital Clínico Universitario, A Coruña, Spain., Pumar JM; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain.; Department of Neuroradiology, Hospital Clínico Universitario, Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Mosqueira AJ; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain.; Department of Neuroradiology, Hospital Clínico Universitario, Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Fernández-Rodicio S; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Bazarra-Barreiros M; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Serena J; Cerebrovascular Pathology Research Group, Stroke Unit, Department of Neurology, Hospital Universitari Dr. Josep Trueta de Girona, Girona Biomedical Research Institute (IDIBGI), Girona, Spain., Silva-Blas Y; Cerebrovascular Pathology Research Group, Stroke Unit, Department of Neurology, Hospital Universitari Dr. Josep Trueta de Girona, Girona Biomedical Research Institute (IDIBGI), Girona, Spain., Gubern-Merida C; Cerebrovascular Pathology Research Group, Girona Biomedical Research Institute (IDIBGI), Parc Hospitalari Martí I Julià, Salt, Spain., Rey-Aldana D; Centro de Salud de A Estrada, Area Sanitaria de Santiago de Compostela, A Estrada, Spain., Cinza S; Centro de Saúde O Milladoiro, Santiago de Compostela, Spain., Campos F; Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Sobrino T; NeuroAging Laboratory Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Castillo J; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Alonso-Alonso ML; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain., Iglesias-Rey R; Neuroimaging and Biotechnology Laboratory (NOBEL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), A Coruña, Spain.
المصدر: European journal of clinical investigation [Eur J Clin Invest] 2024 Jun; Vol. 54 (6), pp. e14181. Date of Electronic Publication: 2024 Feb 15.
نوع المنشور: Journal Article; Observational Study; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 0245331 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2362 (Electronic) Linking ISSN: 00142972 NLM ISO Abbreviation: Eur J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley
Original Publication: Berlin, New York, Springer-Verlag, on behalf of the European Society for Clinical Investigation.
مواضيع طبية MeSH: Biomarkers*/blood , Biomarkers*/metabolism , Medical Futility* , Reperfusion* , Cytokine TWEAK*/metabolism, Humans ; Female ; Male ; Aged ; Retrospective Studies ; Middle Aged ; Aged, 80 and over ; Ischemic Stroke ; Leukoaraiosis ; Leukocyte Count ; ROC Curve ; Cohort Studies
مستخلص: Background: Successful recanalization does not lead to complete tissue reperfusion in a considerable percentage of ischemic stroke patients. This study aimed to identify biomarkers associated with futile recanalization. Leukoaraiosis predicts poor outcomes of this phenomenon. Soluble tumour necrosis factor-like weak inducer of apoptosis (sTWEAK), which is associated with leukoaraiosis degrees, could be a potential biomarker.
Methods: This study includes two cohorts of ischemic stroke patients in a multicentre retrospective observational study. Effective reperfusion, defined as a reduction of ≥8 points in the National Institutes of Health Stroke Scale (NIHSS) within the first 24 h, was used as a clinical marker of effective reperfusion.
Results: In the first cohort study, female sex, age, and high NIHSS at admission (44.7% vs. 81.1%, 71.3 ± 13.7 vs. 81.1 ± 6.7; 16 [13, 21] vs. 23 [17, 28] respectively; p < .0001) were confirmed as predictors of futile recanalization. ROC curve analysis showed that leukocyte levels (sensitivity of 99%, specificity of 55%) and sTWEAK level (sensitivity of 92%, specificity of 88%) can discriminate between poor and good outcomes. Both biomarkers simultaneously are higher associated with outcome after effective reperfusion (OR: 2.17; CI 95% 1.63-4.19; p < .0001) than individually (leukocytes OR: 1.38; CI 95% 1.00-1.64, p = .042; sTWEAK OR: 1.00; C I95% 1.00-1.01, p = .019). These results were validated using a second cohort, where leukocytes and sTWEAK showed a sensitivity of 100% and specificity of 66.7% and 75% respectively.
Conclusions: Leukocyte and sTWEAK could be biomarkers of reperfusion failure and subsequent poor outcomes. Further studies will be necessary to explore its role in reperfusion processes.
(© 2024 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.)
References: GBD 2019 stroke collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. Neurol. 2021;20(10):795‐820.
World Health Organization. Global Health Estimates: Life expectancy and leading causes of death and disability. Available from: https://www.who.int/data/gho/data/themes/mortality‐and‐global‐health‐estimates.
Wafa HA, Wolfe CDA, Emmett E, Roth GA, Johnson CO, Wang Y. Burden of stroke in Europe. Stroke. 2020;51(8):2418‐2427.
Rochmah TN, Rahmawati IT, Dahlui M, Budiarto W, Bilqis N. Economic burden of stroke disease: a systematic review. Int J Environ Res Public Health. 2021;18(14):7552.
Luengo‐Fernandez R, Violato M, Candio P, Leal J. Economic burden of stroke across Europe: a population‐based cost analysis. Eur Stroke J. 2020;5(1):17‐25.
Lopez‐Bastida J, Oliva Moreno J, Worbes Cerezo M, Perestelo Perez L, Serrano‐Aguilar P, Montón‐Álvarez F. Social and economic costs and health‐related quality of life in stroke survivors in the Canary Islands, Spain. BMC Health Serv Res. 2012;12(1):315.
Rudberg AS, Berge E, Gustavsson A, Näsman P, Lundström E. Long‐term health‐related quality of life, survival and costs by different levels of functional outcome six months after stroke. Eur Stroke J. 2018;3(2):157‐164.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics‐2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93‐e621.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American stroke. Stroke. 2019;50(12):e344‐e418.
Alonso de Leciñana M, Egido JA, Casado I, et al. Guidelines for the treatment of acute ischaemic stroke. Neurologia. 2014;29(2):102‐122.
Campbell BC. Thrombolysis and thrombectomy for acute ischemic stroke: strengths and synergies. Semin Thromb Hemost. 2016;43(2):185‐190.
Patil S, Rossi R, Jabrah D, Doyle K. Detection, diagnosis and treatment of acute ischemic stroke: current and future perspectives. Front Med Technol. 2022;4:748949.
Jolugbo P, Ariëns RAS. Thrombus composition and efficacy of thrombolysis and thrombectomy in acute ischemic stroke. Stroke. 2021;52(3):1131‐1142.
Mosconi MG, Paciaroni M. Treatments in ischemic stroke: current and future. Eur Neurol. 2022;85(5):349‐366.
Flottmann F, Broocks G, Faizy TD, et al. Factors associated with failure of reperfusion in endovascular therapy for acute ischemic stroke. Clin Neuroradiol. 2021;31(1):197‐205.
Ni H, Liu X, Hang Y, et al. Predictors of futile recanalization in patients with acute ischemic stroke undergoing mechanical thrombectomy in late time windows. Front Neurol. 2022;13:958236.
Hussein HM, Saleem MA, Qureshi AI. Rates and predictors of futile recanalization in patients undergoing endovascular treatment in a multicenter clinical trial. Neuroradiology. 2018;60(5):557‐563.
Dhillon PS, Butt W, Marei O, et al. Incidence and predictors of poor functional outcome despite complete recanalisation following endovascular thrombectomy for acute ischaemic stroke. J Stroke Cerebrovasc Dis. 2023;32(5):107083.
Iglesias‐Rey R, Rodríguez‐Yáñez M, Rodríguez‐Castro E, et al. Worse outcome in stroke patients treated with rt‐PA without early reperfusion: associated factors. Transl Stroke Res. 2018;9(4):347‐355.
Pan H, Lin C, Chen L, et al. Multiple‐factor analyses of futile recanalization in acute ischemic stroke patients treated with mechanical thrombectomy. Front Neurol. 2021;12:704088.
Meinel TR, Lerch C, Fischer U, et al. Multivariable prediction model for futile recanalization therapies in patients with acute ischemic stroke. Neurology. 2022;99(10):e1009‐e1018.
Shahid AH, Abbasi M, Larco JLA, et al. Risk factors of futile recanalization following endovascular treatment in patients with large‐vessel occlusion: systematic review and meta‐analysis. Stroke Vasc Interv Neurol. 2022;2(6):e000257.
Chen X, Wang J, Ge L, et al. A fibrin targeted molecular imaging evaluation of microvascular no‐reflow in acute ischemic stroke. Brain Behav. 2022;12(2):e2474.
Gilberti N, Gamba M, Premi E, et al. Leukoaraiosis is a predictor of futile recanalization in acute ischemic stroke. J Neurol. 2017;264(3):448‐452.
Kaginele P, Beer‐Furlan A, Joshi KC, et al. Brain atrophy and leukoaraiosis correlate with futile stroke thrombectomy. J Stroke Cerebrovasc Dis. 2021;30(8):105871.
da Silva‐Candal A, Custodia A, López‐Dequidt I, et al. sTWEAK is a leukoaraiosis biomarker associated with neurovascular angiopathy. Ann Clin Transl Neurol. 2022;9(2):171‐180.
Montaner J, Alvarez‐Sabín J. NIH stroke scale and its adaptation to Spanish. Neurologia. 2006;21(4):192‐202.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604‐607.
White JA, Hart RJ, Fry JC. An evaluation of the waters Pico‐tag system for the amino‐acid analysis of food materials. J Automat Chem. 1986;8(4):170‐177.
Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24(1):35‐41.
Kloner RA, King KS, Harrington MG. No‐reflow phenomenon in the heart and brain. Am J Physiol Heart Circ Physiol. 2018;315(3):H550‐H562.
Amki ME, Wegener S. Reperfusion failure despite recanalization in stroke: new translational evidence. Clin Transl Neurosci. 2021;5(1):1‐7.
Hu J, Nan D, Lu Y, et al. Microcirculation No‐reflow phenomenon after acute ischemic stroke. Eur Neurol. 2023;86(2):85‐94.
Rodríguez‐Castro E, López‐Dequit I, Santamaría‐Cadavid M, et al. Trends in stroke outcomes in the last ten years in a European tertiary hospital. BMC Neurol. 2018;18(1):164.
Jurcau A, Simion A. Neuroinflammation in cerebral ischemia and ischemia/reperfusion injuries: from pathophysiology to therapeutic strategies. Int J Mol Sci. 2022;23(1):14.
Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic stroke: translational insights from experimental studies. J Cereb Blood Flow Metab. 2015;35(6):888‐901.
Chen J, Zhang Z, Chen L, et al. Correlation of changes in leukocytes levels 24 hours after intravenous thrombolysis with prognosis in patients with acute ischemic stroke. J Stroke Cerebrovasc Dis. 2018;27(10):2857‐2862.
Malhotra K, Goyal N, Chang JJ, et al. Differential leukocyte counts on admission predict outcomes in patients with acute ischaemic stroke treated with intravenous thrombolysis. Eur J Neurol. 2018;25(12):1417‐1424.
El Amki M, Glück C, Binder N, et al. Neutrophils obstructing brain capillaries are a major cause of No‐reflow in ischemic stroke. Cell Rep. 2020;33(2):108260.
del Zoppo GJ, Schmid‐Schönbein GW, Mori E, Copeland BR, Chang CM. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke. 1991;22(10):1276‐1283.
Rolfes L, Riek‐Burchardt M, Pawlitzki M, et al. Neutrophil granulocytes promote flow stagnation due to dynamic capillary stalls following experimental stroke. Brain Behav Immun. 2021;93:322‐330.
Yata K, Nishimura Y, Unekawa M, et al. In vivo imaging of the mouse neurovascular unit under chronic cerebral hypoperfusion. Stroke. 2014;45(12):3698‐3703.
Winkles JA. The TWEAK‐Fn14 cytokine‐receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7(5):411‐425.
Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14(3–4):241‐249.
Blanco‐Colio LM, Martín‐Ventura JL, Muñóz‐García B, et al. Identification of soluble tumor necrosis factor‐like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2007;27(4):916‐922.
Blanco‐Colio LM. TWEAK/Fn14 axis: a promising target for the treatment of cardiovascular diseases. Front Immunol. 2014;5:3.
Dai J‐X, Cai J‐Y, Sun J, Lin Q, Yu ZQ. Serum soluble tumor necrosis factor‐like weak inducer of apoptosis is a potential biomarker for outcome prediction of patients with aneurysmal subarachnoid hemorrhage. Clin Chim Acta. 2020;510:354‐359.
Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST‐elevation myocardial infarction and related to an adverse short‐term outcome. Atherosclerosis. 2010;211(1):322‐326.
Hervella P, Pérez‐Mato M, Rodríguez‐Yáñez M, et al. sTWEAK as predictor of stroke recurrence in ischemic stroke patients treated with reperfusion therapies. Front Neurol. 2021;12:652867.
Iglesias‐Rey R, Custodia A, Alonso‐Alonso ML, et al. The smoking paradox in stroke patients under reperfusion treatment is associated with endothelial dysfunction. Front Neurol. 2022;13:841484.
Comertpay E, Vural S, Eroğlu O, Dindar Badem N, Karadeniz Bilgili Y, Coşkun F. The diagnostic value of sTWEAK in acute ischemic stroke. Balkan Med J. 2020;37:336‐340.
Yepes M. TWEAK and Fn14 in the neurovascular unit. Front Immunol. 2013;4:367.
Chen T, Guo Z, Li L, et al. TWEAK enhances E‐selectin and ICAM‐1 expression, and may contribute to the development of cutaneous vasculitis. PLoS One. 2013;8(2):e56830.
Haile WB, Echeverry R, Wu J, Yepes M. The interaction between tumor necrosis factor‐like weak inducer of apoptosis and its receptor fibroblast growth factor‐inducible 14 promotes the recruitment of neutrophils into the ischemic brain. J Cereb Blood Flow Metab. 2010;30(6):1147‐1156.
معلومات مُعتمدة: RD21/0006/0003 RICORS-ICTUS; RD21/0006/0011 RICORS-ICTUS; PDC2021-121455-I00 Ministerio de Ciencia e Innovación; SAF2017-84267-R Ministerio de Ciencia e Innovación; RD16/0019/0001 RETICS-INVICTUS; RD16/0019/0003 RETICS-INVICTUS; CP22/00061 Instituto de Salud Carlos III; CPII17/00027 Instituto de Salud Carlos III; CPII19/00020 Instituto de Salud Carlos III; FI22/00200 Instituto de Salud Carlos III; PI17/00540 Instituto de Salud Carlos III; PI17/01103 Instituto de Salud Carlos III; PI21/01256 Instituto de Salud Carlos III; DTS/00103 Instituto de Salud Carlos III; IN607A2022-03 Xunta de Galicia
فهرسة مساهمة: Keywords: No‐reflow phenomenon; acute ischemic stroke; biomarkers; futile recanalization; sTWEAK
تواريخ الأحداث: Date Created: 20240216 Date Completed: 20240514 Latest Revision: 20240612
رمز التحديث: 20240612
DOI: 10.1111/eci.14181
PMID: 38361320
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2362
DOI:10.1111/eci.14181